Published in Healthcare Mergers, Acquisitions and Ventures Week, July 21st, 2007
Under the terms of the transaction, Peregrine will receive approximately $22.5 million in gross proceeds in exchange for up to 30,000,000 shares of its common stock. Net proceeds following the payment of sales commissions and other expenses of the offering are expected to be approximately $20.9 million....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.